Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
WuXi AppTec reported it has been given a certificate of...
China’s central government spent $38.4 billion on...
AstraZeneca will spend $200 million to build a major new...
WuXi PharmaTech, a leading China CRO, has acquired...
WuXi PharmaTech will acquire two related China...
BioBay, the Suzhou life science park, formed a cancer...
WuXi PharmaTech has formed a $50 million corporate...
China National Biotechnology Group (CNBG) will raise as...
WuXi PharmaTech and ShangPharma are both attractive M&A...
WuXi PharmaTech and ShangPharma are both attractive M&A...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
